0 CHECKOUT

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

  • ID: 3691287
  • August 2016
  • Region: Global
  • La Merie Publishing
1 of 2
Branded Therapeutic Antibodies on the Market Reached Global Sales of US$ 91.5 Bln in the Year 2015, with a Growth Rate of 11.3% Compared with the Previous Year

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Therapeutic monoclonal antibodies have become a clinically and commercially successful class of drugs. Branded therapeutic antibodies on the market reached global sales of US$ 91.5 bln in the year 2015, with a growth rate of 11.3% compared with the previous year. Despite the emergence of biosimilar antibodies due to patent expiries, validation of new targets, such as immune checkpoint molecules, and of new antibody technologies enable the generation of innovative and IP-protected antibodies fostering further growth of the therapeutic antibody market. Among the enabling antibody technologies are

- Fc-engineering of antibodies,
- antibody-drug conjugates,
- T-cell redirecting antibodies,
- bispecific antibodies and
- oligo- and polyclonal antibody formats.

These technologies also allow to revisit so far unsuccessful antibody targets. Immuno-oncology is one of the most dynamic R&D fields in the industry, so far mainly based on immune checkpoint inhibitor antibodies targeting PD-1 and PD-L1 alone and in combination with a vast variety of other approaches for cancer therapy.

Product READ MORE >

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Amgen Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Beckman Coulter, Inc.
  • Novartis AG
  • Baxter International Inc.